journal
Journals European Neuropsychopharmacolo...

European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology

https://read.qxmd.com/read/37247462/disease-progression-to-bipolar-disorder-among-adolescents-and-young-adults-with-antidepressant-resistant-and-antidepressant-responsive-depression-does-antidepressant-class-matter
#1
JOURNAL ARTICLE
Ju-Wei Hsu, Li-Chi Chen, Shih-Jen Tsai, Kai-Lin Huang, Ya-Mei Bai, Tung-Ping Su, Tzeng-Ji Chen, Mu-Hong Chen
Studies have demonstrated a positive relationship between antidepressant resistance and the progression of bipolar disorder. However, the influence of antidepressant classes such as selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) in this context has yet to be investigated. A total of 5,285 adolescents and young adults with antidepressant-resistant depression and 21,140 with antidepressant-responsive depression were recruited in the present study. The antidepressant-resistant depression group was divided into two subgroups: only resistant to SSRIs (n = 2,242, 42...
May 27, 2023: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/37182458/comparing-the-pharmacology-and-pharmacokinetics-of-antipsychotics-choosing-an-antipsychotic-and-dosing-a-long-acting-injectable
#2
REVIEW
Stephen M Stahl, Gorica Djokic
In this paper, we will discuss the pharmacologic properties of antipsychotics, including those that are the same in structure and those that differentiate one from another. We will bring to you how differential pharmacologic properties can explain differential efficacy and differential tolerability. We will review how to use plasma drug levels and long-acting injectables to enhance compliance early in the illness, and to manage both forms of treatment resistance (pharmacokinetic and pharmacodynamic failures)...
May 12, 2023: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/37156112/expression-of-the-transient-receptor-potential-vanilloid-1-ion-channel-in-the-supramammillary-nucleus-and-the-antidepressant-effects-of-its-antagonist-amg9810-in-mice
#3
JOURNAL ARTICLE
Khai Huynh Ngoc, Angéla Kecskés, Eszter Kepe, Liza Nabi, Julie Keeble, Éva Borbély, Zsuzsanna Helyes
The Transient Receptor Potential Vanilloid 1 (TRPV1) non-selective cation channel predominantly expressed in primary sensory neurons of the dorsal root and trigeminal ganglia mediates pain and neurogenic inflammation. TRPV1 mRNA and immunoreactivity were described in the central nervous system (CNS), but its precise expression pattern and function have not been clarified. Here we investigated Trpv1 mRNA expression in the mouse brain using ultrasensitive RNAScope in situ hybridization. The role of TRPV1 in anxiety, depression-like behaviors and memory functions was investigated by TRPV1-deficient mice and pharmacological antagonism by AMG9810...
May 6, 2023: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/37148637/esketamine-in-treatment-resistant-depression-patients-comorbid-with-substance-use-disorder-a-viewpoint-on-its-safety-and-effectiveness-in-a-subsample-of-patients-from-the-real-esk-study
#4
JOURNAL ARTICLE
Stefania Chiappini, Giacomo d'Andrea, Sergio De Filippis, Marco Di Nicola, Ileana Andriola, Roberta Bassetti, Stefano Barlati, Mauro Pettorruso, Stefano Sensi, Massimo Clerici, Bernardo Dell'Osso, Antonio Vita, Giovanni Martinotti
Esketamine, the S-enantiomer of ketamine, has recently emerged as a therapy for treatment-resistant depression (TRD), showing both rapid antidepressant action and good efficacy and high safety. It is also indicated for the acute short-term treatment of psychiatric emergency due to major depressive disorder (MDD) and for depressive symptoms in adults with MDD with acute suicidal thoughts/behavior. We here provide preliminary insights on esketamine nasal spray (ESK-NS) effectiveness and safety among patients with a substance use disorder (SUD) within the sample of patients with TRD collected for the observational, retrospective, multicentre REAL-ESK study...
May 4, 2023: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/37148631/immunoinflammatory-and-oxidative-alterations-in-subjects-with-schizophrenia-under-clozapine-a-meta-analysis
#5
REVIEW
Paulo Levi Bezerra Martins, Ian Araújo Moura, Gabrielle Mendes, Vitória Cristina Almeida Flexa Ribeiro, André Arnaud, Clarissa S Gama, Michael Maes, Danielle S Macedo, Joel Porfirio Pinto
Clozapine presents immunoregulatory properties not well understood. To address this issue, we performed this systematic review to evaluate the immune alterations induced by clozapine and its relationship with the drug's clinical response and compare it with other antipsychotics. Our systematic review has selected nineteen studies meeting the inclusion criteria, from which eleven were included in the meta-analysis, totalizing 689 subjects distributed over three different comparisons. The results revealed that clozapine treatment activates the compensatory immune-regulatory system (CIRS) (Hedges's g = +1...
May 4, 2023: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/37126998/contributions-of-circadian-clock-genes-to-cell-survival-in-fibroblast-models-of-lithium-responsive-bipolar-disorder
#6
JOURNAL ARTICLE
Himanshu K Mishra, Heather Wei, Kayla E Rohr, Insu Ko, Caroline M Nievergelt, Adam X Maihofer, Paul D Shilling, Martin Alda, Wade H Berrettini, Kristen J Brennand, Joseph R Calabrese, William H Coryell, Mark Frye, Fred Gage, Elliot Gershon, Melvin G McInnis, John Nurnberger, Ketil J Oedegaard, Peter P Zandi, John R Kelsoe, Michael J McCarthy
Bipolar disorder (BD) is characterized by mood episodes, disrupted circadian rhythms and gray matter reduction in the brain. Lithium is an effective pharmacotherapy for BD, but not all patients respond to treatment. Lithium has neuroprotective properties and beneficial effects on circadian rhythms that may distinguish lithium responders (Li-R) from non-responders (Li-NR). The circadian clock regulates molecular pathways involved in apoptosis and cell survival, but how this overlap impacts BD and/or lithium responsiveness is unknown...
April 29, 2023: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/37126871/a-randomized-controlled-trial-of-add-on-naproxen-simvastatin-and-their-combination-for-the-treatment-of-schizophrenia-or-schizoaffective-disorder
#7
JOURNAL ARTICLE
Mark Weiser, Linda Levi, Jinyoung Park, Igor Nastas, Valentin Matei, Michael Davidson, Ido Arad, Israel Dudkiewicz, John M Davis
This large randomized controlled trial examined the effect of naproxen, simvastatin or both on patients with schizophrenia. This was a large multi-center, twelve-week, randomized, double-blind, placebo-controlled, four-arm clinical trial administering naproxen, simvastatin or both to 232 subjects with schizophrenia or schizoaffective disorder. The primary outcome was change in PANSS total score. ANCOVA and mixed model analyses of the PANSS total score change showed no significant difference between naproxen and placebo (adjusted p = 0...
April 29, 2023: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/37119561/prediction-of-postpartum-depression-with-an-online-neurocognitive-risk-screening-tool-for-pregnant-women
#8
JOURNAL ARTICLE
Anne Juul Bjertrup, Mette Skovgaard Væver, Kamilla Woznica Miskowiak
Postpartum depression (PPD) is a severe mental illness affecting 10-15% of mothers. Emerging evidence indicates that negative neurocognitive bias in response to infant distress during pregnancy marks an increased risk of PPD. This proof-of-concept study aimed to investigate the association between negatively biased neurocognitive processing of infant distress during pregnancy and subsequent PPD and to explore the feasibility of an online risk screening tool. In the second or third trimester of pregnancy, 87 participants underwent two online tests of reactivity to and evaluation of infant distress and completed questionnaires regarding psychosocial risk factors...
April 27, 2023: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/37119559/psychopathology-for-the-twenty-first-century-towards-a-chatgpt-psychopathology
#9
JOURNAL ARTICLE
Manuel J Cuesta
No abstract text is available yet for this article.
April 27, 2023: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/37119558/the-long-path-ahead-of-robotics-in-psychiatry
#10
LETTER
Gerard Anmella, Miriam Sanabra, Ariadna Mas-Musons, Diego Hidalgo-Mazzei
No abstract text is available yet for this article.
April 27, 2023: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/37119557/why-does-non-adherence-to-treatment-remain-a-leading-cause-of-relapse-in-patients-with-bipolar-disorder
#11
JOURNAL ARTICLE
Ludovic Samalin, Raoul Belzeaux
No abstract text is available yet for this article.
April 27, 2023: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/37119556/a-systematic-review-of-manic-hypomanic-and-depressive-switches-in-patients-with-bipolar-disorder-in-naturalistic-settings-the-role-of-antidepressant-and-antipsychotic-drugs
#12
REVIEW
Margherita Barbuti, Giulia Menculini, Norma Verdolini, Isabella Pacchiarotti, Georgios D Kotzalidis, Alfonso Tortorella, Eduard Vieta, Giulio Perugi
The present systematic review was aimed at critically summarizing the evidence about treatment-emergent manic/hypomanic and depressive switches during the course of bipolar disorder (BD). A systematic search of the MEDLINE, EMBASE, CINAHL, Web of Science, and PsycInfo electronic databases was conducted until March 24th, 2021, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Observational studies clearly reporting data regarding the prevalence of treatment-emergent mood switches in patients with BD were considered for inclusion...
April 27, 2023: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/37094409/anxiolytic-effects-of-endocannabinoid-enhancing-compounds-a-systematic-review-and-meta-analysis
#13
REVIEW
Caroline M B Kwee, Nadia A Leen, Rian C Van der Kamp, Caspar J Van Lissa, Danielle C Cath, Lucianne Groenink, Johanna M P Baas
The endocannabinoid system is a promising candidate for anxiolytic therapy, but translation to the clinic has been lagging. We meta-analyzed the evidence for anxiety-reduction by compounds that facilitate endocannabinoid signaling in humans and animals. To identify areas of specific potential, effects of moderators were assessed. Literature was searched in Pubmed and Embase up to May 2021. A placebo/vehicle-control group was required and in human studies, randomization. We excluded studies that co-administered other substances...
April 22, 2023: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/37121166/the-direct-correlation-between-covid-19-and-attention-deficit-hyperactivity-disorder-adhd
#14
LETTER
Francesco Ferrara, Esteban Zavaleta, Antonio Vitiello, Jorge Arturo Villalobos, Andrea Zovi, Roberto Langella, Bruno Serrano, Ugo Trama, Sebastian Arguedas, Eduardo Nava, Jose Pablo Diaz, Elvira Bianco, Giuseppe Russo
No abstract text is available yet for this article.
April 21, 2023: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/37087864/efficacy-and-safety-of-selegiline-across-different-psychiatric-disorders-a-systematic-review-and-meta-analysis-of-oral-and-transdermal-formulations
#15
JOURNAL ARTICLE
Flavia Rossano, Claudio Caiazza, Andrea Sobrino, Niccolò Solini, Alessandro Vellucci, Nicolas Zotti, Michele Fornaro, Ken Gillman, Carlo Ignazio Cattaneo, Vincent Van den Eynde, Tom K Birkenhager, Henricus G Ruhé, Stephen Stahl, Felice Iasevoli, Andrea de Bartolomeis
Selegiline is an irreversible, selective type-B monoamine oxidase inhibitor (MAOI) approved for Parkison's disease-oral and major depressive disorder-transdermal formulation) resulting in non-selective MAOI activity at oral doses≥20 mg/day. The present systematic review and meta-analysis appraises the evidence of different formulations/dosages of selegiline across different psychiatric conditions. We inquired PubMed/MEDLINE/Cochrane-Central/WHO-ICTRP/Clarivate-WebOfScience and the Chinese-Electronic-Journal Database from inception to 10/26/2022 for selegiline trials involving psychiatric patients...
April 21, 2023: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/37086715/double-dissociation-of-perirhinal-nicotinic-acetylcholine-receptors-and-dopamine-d2-receptors-in-modulation-of-object-memory-consolidation-by-nicotine-cocaine-and-their-conditioned-stimuli
#16
JOURNAL ARTICLE
Michael Wolter, Thomas Lapointe, Nana Baidoo, Krista A Mitchnick, Cassidy Wideman, Boyer D Winters, Francesco Leri
There are indications that drug conditioned stimuli (CS) may activate neurochemical systems of memory modulation that are activated by the drugs themselves. To directly test this hypothesis, a cholinergic nicotinic receptor antagonist (mecamylamine; MEC: 0, 10 or 30 µg/side) and a dopamine D2 receptor antagonist (l-741,626: 0, 0.63, 2.5 µg/side) were infused in the perirhinal cortex (PRh) to block modulation of object recognition memory consolidation induced by 0.4 mg/kg nicotine, 20 mg/kg cocaine, or their CSs...
April 20, 2023: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/37119560/the-impact-of-the-covid-19-pandemic-on-adhd-medicine-consumption-in-47-countries-and-regions
#17
JOURNAL ARTICLE
Sophie Gimbach, Daniel Vogel, Roland Fried, Stephen V Faraone, Tobias Banaschewski, Jan Buitelaar, Manfred Döpfner, Richard Ammer
The objective of this study is to quantify the impact of the COVID-19 pandemic on attention deficit hyperactivity disorder (ADHD) medication consumption globally and nationally using pharmaceutical sales data from 2014 to 2021 across 47 countries and regions. A seasonal autoregressive integrated moving average model (SARIMA) was applied to the time series until the end of 2019 at country level and used for the prediction of the ADHD medication consumption in 2020 and 2021. The deviations from the actual to the forecasted sales, which simulate the development without the emergence of COVID-19, yield estimates for the pandemic's impact...
April 17, 2023: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/37075639/antipsychotic-induced-akathisia-in-adults-with-acute-schizophrenia-a-systematic-review-and-dose-response-meta-analysis
#18
JOURNAL ARTICLE
Hui Wu, Spyridon Siafis, Dongfang Wang, Angelika Burschinski, Johannes Schneider-Thoma, Josef Priller, John M Davis, Stefan Leucht
Antipsychotic-induced akathisia is severely distressing. We aimed to investigate relationships between antipsychotic doses and akathisia risk. We searched for randomised controlled trials that investigated monotherapy of 17 antipsychotics in adults with acute schizophrenia until 06 March 2022. The primary outcome was the number of participants with akathisia, which was analysed with odds ratios (ORs). We applied one-stage random-effects dose-response meta-analyses using restricted cubic splines to model the dose-response relationships...
April 17, 2023: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/37075594/impact-of-antidepressant-use-on-the-autonomic-nervous-system-a-meta-analysis-and-systematic-review
#19
REVIEW
Dimitri Fiani, Hannah Campbell, Marco Solmi, Jess G Fiedorowicz, Chadi A Calarge
Changes in cardiac autonomic nervous system (ANS) regulation observed in psychiatric disorders may be mitigated by antidepressants. We meta-analyzed and systematically reviewed studies examining antidepressants' effects on ANS outcomes, including heart rate variability (HRV). We conducted a PRISMA/MOOSE-compliant search of PubMed and Scopus until March 28th, 2022. We included randomized placebo-controlled trials (RCTs) and pre-post studies, regardless of diagnosis. We pooled results in random-effects meta-analyses, pooling homogeneous study designs and outcomes...
April 17, 2023: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/37060629/antidepressant-efficacy-of-cariprazine-in-bipolar-disorder-and-the-role-of-its-pharmacodynamic-properties-a-hypothesis-based-on-data
#20
REVIEW
Konstantinos N Fountoulakis, Magdalini Ioannou, Mauricio Tohen, Bartholomeus C M Haarman, Carlos A Zarate
The treatment of bipolar depression is one of the most challenging needs in contemporary psychiatry. Currently, only quetiapine, olanzapine-fluoxetine combination, lurasidone, cariprazine, and recently lumateperone have been FDA-approved to treat this condition. The neurobiology of bipolar depression and the possible targets of bipolar antidepressant therapy remain elusive. The current study investigated whether the pharmacodynamic properties of cariprazine fit into a previously developed model which was the first to be derived based on the strict combination of clinical and preclinical data...
April 13, 2023: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
journal
journal
30810
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.